Lercanidipina Mepha

Lercanidipine, the active ingredient in Lercanidipina Mepha, is a calcium channel blocker presented as an oral tablet for oral administration. Approved in the European Union, it is used to treat hypertension in adult patients, assisting in lowering elevated blood pressure and decreasing cardiovascular risk.

GNH USA supplies Lercanidipina Mepha as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with a focus on quality assurance and regulatory compliance.

Lercanidipine is indicated for the management of hypertension, a condition characterized by chronically elevated arterial pressure.

- Essential hypertension: reduces systolic and diastolic blood pressure, improving cardiovascular outcomes. - Isolated systolic hypertension: lowers systolic pressure, helping to prevent stroke and heart disease.

Lercanidipine may be associated with several adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Headache: mild to moderate intensity, often transient. - Flushing: sensation of warmth and redness, usually short‑lived. - Peripheral edema: swelling of ankles or feet, may require monitoring. - Dizziness: especially upon standing, related to blood pressure lowering. - Tachycardia: increased heart rate, generally mild. - Fatigue: general feeling of tiredness.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure requiring medical attention. - Angioedema: swelling of face, lips, tongue, potentially airway‑compromising. - Myocardial infarction: rare occurrence of heart attack. - Hepatic injury: abnormal liver function tests or hepatitis. - Allergic reactions: rash, urticaria, or anaphylaxis. - Cardiac conduction disorders: heart block or arrhythmias.

When prescribing Lercanidipine, clinicians should consider several safety measures. - Blood pressure monitoring: regularly assess to avoid excessive hypotension. - Liver function: evaluate in patients with hepatic impairment. - Elderly patients: start at lower dose and monitor for dizziness. - Concomitant antihypertensives: adjust doses to prevent additive effects. - Discontinuation: avoid abrupt cessation; taper if necessary. - Store at room temperature: keep in the original packaging, protect from moisture and direct sunlight.

Lercanidipine can interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase plasma levels. - Grapefruit juice: can elevate drug concentration, raising risk of hypotension. - Other calcium channel blockers: additive vasodilatory effect. - Concurrent antihypertensives (e.g., ACE inhibitors, ARBs): may cause excessive blood pressure drop. - Rifampicin: induces metabolism, reducing effectiveness.

Moderate Interactions (Monitor Closely): - Diuretics: may enhance orthostatic hypotension. - Beta‑blockers: monitor heart rate and blood pressure. - ACE inhibitors or ARBs: watch for renal function changes. - NSAIDs: may blunt antihypertensive response. - Digoxin: monitor serum levels for potential toxicity.